June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Evaluation of different classes of RBP4 antagonists as potential treatments for AMD
Author Affiliations & Notes
  • Nicoleta Dobri
    OPHTHALMOLOGY, COLUMBIA UNIVERSITY, NEW YORK, NY
  • Qiong Qin
    OPHTHALMOLOGY, COLUMBIA UNIVERSITY, NEW YORK, NY
  • Jian Kong
    OPHTHALMOLOGY, COLUMBIA UNIVERSITY, NEW YORK, NY
  • Rando Allikmets
    OPHTHALMOLOGY, COLUMBIA UNIVERSITY, NEW YORK, NY
    PATHOLOGY, COLUMBIA UNIVERSITY, NEW YORK, NY
  • Janet Sparrow
    OPHTHALMOLOGY, COLUMBIA UNIVERSITY, NEW YORK, NY
    PATHOLOGY, COLUMBIA UNIVERSITY, NEW YORK, NY
  • Konstantin Petrukhin
    OPHTHALMOLOGY, COLUMBIA UNIVERSITY, NEW YORK, NY
  • Footnotes
    Commercial Relationships Nicoleta Dobri, None; Qiong Qin, None; Jian Kong, None; Rando Allikmets, None; Janet Sparrow, None; Konstantin Petrukhin, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1703. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Nicoleta Dobri, Qiong Qin, Jian Kong, Rando Allikmets, Janet Sparrow, Konstantin Petrukhin; Evaluation of different classes of RBP4 antagonists as potential treatments for AMD. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1703.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Pharmacological inhibition of the retinol-induced interaction of Retinol-Binding Protein 4 (RBP4) with transthyretin (TTR) in the serum may decrease the uptake of serum retinol to the retina and reduce formation of lipofuscin bisretinoids. A1120 is non-retinoid RBP4 ligand capable of antagonizing retinol-induced RBP4-TTR interaction. Here we present characterization of A1120 and other classes of RBP4 agonists in a battery of in vivo and in vitro assays.

Methods: RBP4 binding potency, ability to antagonize RBP4-TTR interaction and compound specificity were compared for the representatives of different classes of RBP4 antagonists. Specificity of compounds was confirmed in in vitro assays probing the compound effect on the activity of protein targets capable of binding different types of retinoids. The in vivo effect of compound administration on levels of serum RBP4, visual cycle retinoids, lipofuscin bisretinoids, and retinal visual function was evaluated using a combination of biochemical and electrophysiological techniques

Results: We documented significant reduction of serum RBP4 in response to administration of RBP4 antagonists representing different structural classes. Compound administration induced partial depletion of visual cycle retinoids and significant inhibition of bisretinoid accumulation in the mouse model of enhanced lipofuscinogenesis while no significant changes in kinetics of dark adaptation after the photobleach were evident following long-term compound dosing.

Conclusions: Medicinal chemistry optimization in selected structural series may yield drug candidates with optimized potency and improved pharmacokinetic characteristics which could allow their use in treatment of dry AMD, Stargardt disease and other conditions characterized by excessive lipofuscin accumulation.

Keywords: 412 age-related macular degeneration  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×